Photo: Angiola Harry / Unsplash
The oral drug, sold as Wilserdly, roughly doubled median progression-free survival in the evERA trial's ESR1-mutated group; overall survival data are not yet mature.
Background
Most breast cancers are driven by the estrogen receptor (ER), and endocrine therapy is the backbone of treatment for ER-positive, HER2-negative disease. Over time, tumors can acquire mutations in ESR1, the gene encoding the receptor, which Roche describes as the primary cause of resistance to hormone therapy; the company says up to 40% of patients with HR-positive metastatic breast cancer develop them [2].
Giredestrant, developed by Roche's US subsidiary Genentech, is an oral estrogen receptor antagonist [1]. Roche calls it a next-generation selective estrogen receptor degrader, or SERD [2]. Everolimus, the partner drug, is an established mTOR inhibitor already used in this setting.
What Happened
On November 16, 2026, the FDA approved giredestrant (Wilserdly) in combination with everolimus for adults with ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer, as detected by an FDA-authorized test [1]. Eligible patients must have disease that recurred during or after endocrine-based adjuvant therapy, or progressed after at least one endocrine-based regimen for metastatic disease [1].
The agency also authorized FoundationOne Liquid CDx, a blood-based test, as a companion diagnostic to identify ESR1 mutations [1]. The approval came four weeks ahead of the FDA's goal date and was reviewed under Project Orbis with Health Canada and Israel's Ministry of Health, plus the agency's Assessment Aid program [1]. In regulatory terms, early is the new on time.
The recommended dose is 30 mg orally once daily, with or without food, until disease progression or unacceptable toxicity [1].
Study Design and Limitations
The approval rests on evERA Breast Cancer (NCT05306340), a randomized, open-label, multicenter trial [1]. It enrolled 373 adults with ER-positive, HER2-negative disease, of whom 207 had ESR1-mutated tumors [1]. Patients were randomized 1:1 to giredestrant or the physician's choice of endocrine therapy (exemestane, fulvestrant or tamoxifen); everyone also received everolimus [1]. Roche notes that participants had previously received a CDK4/6 inhibitor and endocrine therapy [2].
In the ESR1-mutated group, median progression-free survival, assessed by investigators, was 10 months with giredestrant plus everolimus versus 5.5 months with standard endocrine therapy plus everolimus (hazard ratio 0.38; 95% CI, 0.27 to 0.54; p<0.0001) [1]. That corresponds to a 62% reduction in the risk of progression or death, Roche said [2]. Objective response rates were 27% versus 14% [1].
Important caveats remain. Overall survival data were immature at the time of the analysis, so it is not yet known whether patients live longer [1]. The trial was open-label and the primary endpoint was investigator-assessed rather than centrally reviewed [1]. The approval covers only the ESR1-mutated population; the FDA announcement does not report results for the full trial population, and Roche's release did not give an intention-to-treat hazard ratio [1,2].
Side effects are substantial, partly reflecting everolimus. Adverse reactions occurring in at least 20% of patients were stomatitis, rash, fatigue, diarrhea, musculoskeletal pain, pneumonitis and nausea [1]. Warnings and precautions include bradycardia and embryo-fetal toxicity [1]. Laboratory abnormalities included decreased blood counts and electrolytes and increased liver enzymes and creatinine [1].
Erica Mayer of Dana-Farber Cancer Institute, quoted in Roche's release, said the results show "prolonged disease control through a fully oral therapeutic option" [2].
What Comes Next
Roche has a separate application pending for giredestrant as adjuvant therapy in stage I to III ER-positive, HER2-negative breast cancer at intermediate to high risk of recurrence, based on the lidERA trial; the FDA accepted it under Priority Review with a goal date of November 30, 2026 [2]. Further readouts from the pionERA and heredERA trials are pending, and the company says filings outside the US are underway [2]. Overall survival from evERA will be the key number to watch.
This article is for informational purposes only and is not medical advice; readers with health questions should consult their clinician.
References
U.S. Food and Drug Administration. FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer. FDA. November 16, 2026. https://www.fda.gov/drugs/cancer-approvals/fda-approves-giredestrant-combination-everolimus-er-positive-her2-negative-esr1-mutated-locally
Roche. FDA approval of Wilserdly (giredestrant) in combination with everolimus for ESR1-mutated advanced breast cancer. Roche media release. November 16, 2026. https://www.roche.com/media/releases/med-cor-2026-11-16b